Related Experiment Video
Updated: Jul 3, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Protein kinase C signalling in leukemia.
Amanda J Redig1, Leonidas C Platanias
1Robert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, Northwestern University Medical School and Lakeside VA Medical Center, Chicago, IL 60611, USA.
Leukemia & Lymphoma
|July 8, 2008
Summary
Protein Kinase C (PKC) isoforms have diverse roles in leukemia, promoting cancer growth or mediating anti-leukemic responses. Understanding these distinct functions offers potential for novel leukemia treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The protein kinase C (PKC) family comprises structurally similar but functionally diverse kinases.
- Distinct PKC isoforms and groups show varied expression and function in different leukemias.
- While some PKC members promote leukemic cell survival, others can induce anti-leukemic effects.
Purpose of the Study:
- To review the role of distinct PKC family members in the pathophysiology of myeloid and lymphoid leukemias.
- To discuss the clinical-therapeutic potential of targeting PKC in leukemia treatment.
- To explore novel therapeutic approaches for various leukemia types based on PKC research.
Main Methods:
- Literature review of studies on PKC isoforms in leukemia.
- Analysis of expression patterns and functional roles of PKC in myeloid and lymphoid leukemias.
- Synthesis of current research on PKC's impact on leukemic cell survival, growth, and anti-leukemic responses.
Main Results:
- PKC isoforms exhibit dual roles in leukemia, influencing both leukemic cell progression and immune-mediated destruction.
- Specific PKC pathways are implicated in the distinct pathophysiology of myeloid versus lymphoid leukemias.
- Evidence suggests that modulating PKC activity could be a viable therapeutic strategy.
Conclusions:
- The diverse functions of PKC isoforms in leukemia highlight their complex involvement in disease progression and treatment response.
- Targeting specific PKC pathways presents a promising avenue for developing novel and effective leukemia therapies.
- Further research into PKC's role can lead to tailored treatment strategies for different leukemia subtypes.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...